ClinicalTrials.gg
Not yet recruitingNCT07948837RUTBEUpdated Nov 19, 2026

Effects of Psychosocial Skills Training on Well-Being and Functioning in People With Psychotic Disorders

An interventional study of RUTBE Psychosocial Skills Training in Psychotic Disorders, Schizophrenia Spectrum Disorders and Bipolar Affective Disorder, sponsored by Ömer USLU. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Ömer USLU · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial aims to evaluate the effects of psychosocial skills training on psychological well-being and functioning in adults with psychotic disorders. People living with psychotic disorders may experience difficulties in communication, daily activities, social relationships, and maintaining psychological well-being. Psychosocial skills training is designed to help individuals develop practical skills for managing these challenges.

The study will include 34 adults diagnosed with psychotic or schizophrenia spectrum disorders who receive care at a community mental health center in Türkiye. Participants will be randomly assigned to an intervention group (17 participants) or a control group (17 participants).

The intervention group will receive eight weekly, face-to-face group sessions of psychosocial skills training (RUTBE), each lasting approximately 90-120 minutes. The sessions will address communication, problem-solving, understanding mental illness and its treatment, coping with symptoms, managing stress, and improving social and daily living skills. The control group will continue receiving routine care without the additional training during the study period.

Psychological well-being and functioning will be assessed in both groups before the training, immediately after the eight-session program, and three months later. The study will examine whether adding psychosocial skills training to routine mental health care improves psychological well-being and functioning compared with routine care alone.

Read the detailed description

This study is designed as a two-arm, parallel-group randomized controlled trial to evaluate the effects of psychosocial skills training on psychological well-being and functioning among individuals with psychotic disorders. The study will be conducted at the Community Mental Health Center affiliated with Söke Fehime Faik Kocagöz State Hospital in Aydın, Türkiye.

A total of 34 participants will be recruited and randomly allocated to an intervention group (n=17) or a control group (n=17) using randomizer.org. Eligible participants will be adults aged 18 years or older who are literate and have a diagnosis of a psychotic or schizophrenia spectrum disorder according to DSM-5 criteria. The treating psychiatrist will assess clinical suitability for participation. Individuals experiencing an acute episode or unable to communicate effectively will be excluded. Written informed consent will be obtained before participation.

The intervention group will receive a structured psychosocial skills training program (RUTBE) based on Liberman's Social and Independent Living Skills Program and the training manual developed by Yıldız. The program will consist of eight weekly, face-to-face group sessions lasting approximately 90-120 minutes each. The sessions will address group preparation and communication, understanding mental illness and daily living skills, cognitive and perceptual disturbances, treatment and medication management, coping with persistent symptoms and early warning signs, avoiding ineffective treatments and substance use, stress management and self-confidence, and improving social functioning. Interactive exercises, role-playing, behavioral rehearsal, feedback, and homework assignments will be used to reinforce skills. Participants may receive homework reminders through telephone calls or messages.

The control group will continue receiving routine mental health care without the additional structured RUTBE program during the intervention and follow-up periods. Following completion of the three-month follow-up assessment, the training will be offered to the control group.

Data will be collected at baseline, immediately after the eight-session intervention, and three months after the intervention. Psychological well-being will be measured using the eight-item Psychological Well-Being Scale, with scores ranging from 8 to 56 and higher scores indicating greater psychological well-being. Functioning will be assessed using the 24-item Functioning Assessment Short Test, with scores ranging from 0 to 72 and higher scores indicating greater functional impairment. A personal information form will be administered at baseline.

The study will compare changes in psychological well-being and functioning between the intervention and control groups over time. The findings may help inform the use of structured psychosocial rehabilitation programs in community mental health services.

02

Conditions studied

  • Psychotic Disorders
  • Schizophrenia Spectrum Disorders
  • Bipolar Affective Disorder

Keywords

  • Psychosocial Skills Training
  • Psychological Well-Being
  • Functional Impairment
  • Randomized Controlled Trial
  • Psychiatric Rehabilitation
03

In context

Psychotic Disorders

1,591 studies on the registry are indexed under Psychotic Disorders; 282 are open to participants now.

This study's planned enrollment of 34 is below the median of 65 across 1,324 interventional studies indexed under Psychotic Disorders.

Browse Psychotic Disorders studies →

Lead sponsor

Ömer USLU is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of a psychotic disorder or schizophrenia spectrum disorder according to diagnostic criteria.
  • Ability to read and write.
  • A diagnosis of a bipolar disorder
  • Age 18 years or older.

Exclusion criteria

Exclusion Criteria:

  • Being in the acute phase of the illness.
  • Being unable or unwilling to communicate effectively.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    RUTBE Psychosocial Skills Training Group

    Participants assigned to the experimental group (n=17) will receive eight weekly, face-to-face group sessions of Ruhsal ve Toplumsal Beceri Eğitimi (RUTBE), a structured psychosocial skills training program, in addition to routine mental health care. Each session will last approximately 90-120 minutes. Psychological well-being and functioning will be assessed at baseline, immediately after the intervention, and three months after the intervention.

    Behavioral: RUTBE Psychosocial Skills Training

  • No intervention
    Routine Care Control Group

    Participants assigned to the control group (n=17) will continue receiving routine mental health care without additional RUTBE psychosocial skills training during the intervention and follow-up periods. Psychological well-being and functioning will be assessed at baseline, immediately after the eight-week intervention period, and three months later. After completion of the follow-up assessment, the RUTBE program will be offered to control group participants.

Interventions

  • BehavioralRUTBE Psychosocial Skills Training

    RUTBE (Ruhsal ve Toplumsal Beceri Eğitimi) is a structured psychosocial skills training program based on Liberman's Social and Independent Living Skills Program and Yıldız's training manual. The intervention consists of eight weekly, face-to-face group sessions lasting approximately 90-120 minutes each. Session topics include group preparation and communication skills; understanding mental health difficulties and daily living skills; cognitive difficulties and psychotic symptoms; treatment, medications, and side effects; coping with persistent symptoms and recognizing early warning signs; substance-related risks and ineffective treatments; stress management and self-confidence; and social functioning and daily routines. The program incorporates interactive learning, skills practice, and homework assignments, with reminders provided by telephone or messages when needed.

06

What researchers measure

Primary outcomes

  1. Change in Psychological Well-Being Scale Score

    Psychological well-being will be assessed using the eight-item Psychological Well-Being Scale (Flourishing Scale). Each item is scored from 1 to 7, yielding a total score ranging from 8 to 56. Higher scores indicate greater psychological well-being. Changes in total scores will be compared between the intervention and control groups across the three assessment points.

    Time frame: Baseline, immediately after the 8-week intervention, and 3 months after intervention completion

  2. Change in Functioning Assessment Short Test (FAST) Total Score

    Functioning will be assessed using the 24-item Functioning Assessment Short Test (FAST). The scale evaluates six domains: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 72. Higher scores indicate greater functional impairment, while lower scores indicate better functioning. Changes in total scores will be compared between the intervention and control groups across the three assessment points.

    Time frame: Baseline, immediately after the 8-week intervention, and 3 months after intervention completion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers due to the sensitive nature of the clinical and psychosocial information collected from individuals diagnosed with psychotic disorders and the need to protect participant confidentiality and privacy. Study findings will be reported in aggregate form without identifying individual participants.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Jul 2027, 5 months later.

Of 459 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 5 months is below that.

Counting every sponsor, half of 461 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948837
Lead sponsor
Ömer USLU
Responsible party
Ömer USLU (Dr. Ömer Uslu, PhD - Principal Investigator, Aydin Adnan Menderes University) — Sponsor-investigator
First posted
Nov 19, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Ömer USLU, PhD
Contact
imerr.uslu@gmail.com
+905418217957

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion